Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
August 27, 2021 at 03:32 pm IST
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 149.748 million compared to CNY 236.569 million a year ago. Operating loss was CNY 30.355 million compared to operating Income of CNY 9.405 million a year ago. Net loss was CNY 27.669 million compared to net income of CNY 6.296 million a year ago. Basic loss per share from continuing operations was CNY 0.0269 compared to basic earnings per share from continuing operations of CNY 0.0061 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
